| |
N0/M0
|
N+
|
M+
|
|---|
|
n (%)
|
n (%)
|
n (%)
|
|---|
|
Tumor center
| | | |
|
VEGF-C+/VEGFR-2+
|
22/14 (64)
|
16/9 (56)
|
14/7 (50)
|
|
VEGF-D+/VEGFR-2+
|
22/16 (73)
|
12/10 (83)
|
11/7 (64)
|
|
VEGFR-2+/pVEGFR-2Tyr1175+
|
19/14 (74)
|
13/11 (85)
|
12/5 (42)
|
|
VEGFR-2+/pVEGFR-2Tyr1214+
|
19/17 (89)
|
13/10 (77)
|
13/11 (85)
|
|
Tumor budding
| | | |
|
VEGF-C+/VEGFR-2+
|
16/12 (75)
|
10/7 (70)
|
10/8 (80)
|
|
VEGF-D+/ VEGFR-2+
|
16/13 (81)
|
10/8 (80)
|
13/8 (62)
|
|
VEGFR-2+/pVEGFR-2Tyr1175+
|
16/11 (69)
|
10/8 (80)
|
12/7 (58)
|
|
VEGFR-2+/pVEGFR-2Tyr1214+
|
16/16 (100)
|
10/9 (90)
|
13/13 (100)
|
- n: total number of ligand positive cases/total number of ligand positive cases with concomitant VEGFR-2 positivity or total number of VEGFR-2 positive cases/total number of VEGFR-2 positive cases with concomitant pVEGFR-2 positivity. There were no significant differences between the groups
